Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis

OBJECTIVE: We aimed to analyze clinical outcomes from patients with severe COVID-19 pneumonia that received either baricitinib plus dexamethasone or dexamethasone monotherapy. METHODOLOGY: We performed a retrospective comparative study. Data from hospitalized patients with severe COVID-19 pneumonia...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Microbiol Immunol Infect
Hlavní autoři: Pérez-Alba, Eduardo, Nuzzolo-Shihadeh, Laura, Aguirre-García, Gloria Mayela, Espinosa-Mora, Jaime, Lecona-Garcia, Juan Diego, Flores-Pérez, Romulo Omar, Mendoza-Garza, Marisela, Camacho-Ortiz, Adrián
Médium: Artigo
Jazyk:Inglês
Vydáno: Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. 2021
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8253716/
https://ncbi.nlm.nih.gov/pubmed/34294593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jmii.2021.05.009
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky